News & Updates

A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.

The MOH and MIMS colorectal screening awareness programme is well under way with the launch of two subsequent education modules. The collaboration is known as “COREC: Battling colorectal cancer together” with the first module launched early 2022.

Taking aspirin daily appears to do nothing in terms of reducing the risk of cutaneous melanoma in older individuals, according to a study.

Adjuvant radiotherapy (RT) may be omitted in women with very low-risk breast cancer who have had breast conserving surgery (BCS) and have been receiving endocrine therapy, according to findings from the LUMINA study.

The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.

Treatment with a novel combination of famitinib, camrelizumab, and nab-paclitaxel appears safe and effective in patients with advanced immunomodulatory triple-negative breast cancer (TNBC), as shown in the results of the phase II FUTURE-C-Plus trial.